Advertisement
Organisation › Details
Lonza Biologics plc (production facility in Slough, UK)
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, the company had sales of CHF 2.690 billion. *
Start | 1993-01-01 established | |
Group | Lonza (Group) | |
Industry | biopharmaceutical | |
Region | Slough, Berkshire | |
Country | United Kingdom (GB) | |
Street | 228 Bath Road | |
City | SL1 4DY Slough, Berkshire | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-04-02 |
Advertisement
More documents for Lonza (Group)
- [1] Lonza Group AG. (4/2/24). "Press Release: Wolfgang Wienand, Currently CEO of Swiss CDMO Siegfried Holding AG, Will Become Chief Executive Officer of Lonza in the Summer of 2024". Basel....
- [2] Lonza Group AG. (3/20/24). "Press Release: Lonza Signs Agreement to Acquire Large-scale Biologics Site in Vacaville (US) from Roche". Basel....
- [3] Cellbox Solutions GmbH. (11/1/23). "Press Release: Dr. Hartmut Tintrup Joins Cellbox Solutions GmbH as new CEO". Cologne....
- [4] Lonza Group AG. (9/18/23). "Press Release: Board Announcement. CEO Pierre-Alain Ruffieux to Leave Lonza – Albert M. Baehny to Step in as CEO ad interim". Basel....
- [5] PolyPeptide Group AG. (8/15/23). "Press Release: Transformational Progress Taking Shape, Profitability Impacted by Rapid Expansion – Appointment of Marc Augustin as New CFO". Baar....
- [6] Lonza Group Ltd.. (6/1/23). "Press Release: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering". Basel & Amsterdam....
- [7] Synaffix B.V.. (1/5/23). "Press Release: Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs". Amsterdam....
- [8] Synaffix B.V.. (1/4/23). "Press Release: Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program". Amsterdam, San Francisco, CA, et al.....
- [9] Emergence Therapeutics AG. (9/6/22). "Press Release: Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal". Amsterdam & Duisburg....
- [10] Rentschler Biopharma SE. (8/18/22). "Press Release: Rentschler Biopharma Appoints Mark Caswell as Vice President, Site Head for US Facility". Laupheim & Milford, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top